Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Joanna Stanisławiak-Rudowicz"'
Autor:
Konrad Lewandowski, Agnieszka Karbownik, Andrzej Czyrski, Hanna Urjasz, Joanna Stanisławiak-Rudowicz, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Acta Poloniae Pharmaceutica, Vol 81, Iss 2, Pp 263-278 (2024)
Olaparib, an oral poly-ADP ribose polymerase (PARP) inhibitor, is a relatively new anticancer drug. It is essential to find TDM-guided dosage for better safety and tolerability of patients. However, first, it is important to develop a suitable analyt
Externí odkaz:
https://doaj.org/article/d88f74306b6e406baae09e6342e10085
Autor:
Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Tomasz Grabowski, Anna Wolc, Joanna Stanisławiak-Rudowicz, Radosław Jaźwiec, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2172 (2021)
A combination of the tyrosine kinase inhibitor—sorafenib—and the opioid analgesic—morphine—can be found in the treatment of cancer patients. Since both are substrates of P-glycoprotein (P-gp), and sorafenib is also an inhibitor of P-gp, their
Externí odkaz:
https://doaj.org/article/eab7ca12e6b04047a2d2383652c3f609
Autor:
Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Andrzej Czyrski, Natalia Kostewicz, Paulina Kaczmarska, Małgorzata Bekier, Joanna Stanisławiak-Rudowicz, Marta Karaźniewicz-Łada, Anna Wolc, Franciszek Główka, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Pharmaceutics, Vol 12, Iss 7, p 600 (2020)
The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and mu
Externí odkaz:
https://doaj.org/article/d7cbe8cda674484da883f39507102113
Publikováno v:
Oncology in Clinical Practice. 17:263-270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce016a6456e4dab668f8e7806733b708
https://doi.org/10.5603/ocp.2021.0037
https://doi.org/10.5603/ocp.2021.0037
Autor:
Agnieszka Karbownik, Joanna Stanisławiak-Rudowicz, Michał Romański, Anna Stachowiak, Edyta Szałek, Edmund Grześkowiak
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objective Sorafenib is an oral, multikinase inhibitor with established single-agent activity in several tumor types. Sorafenib was moderately transported by P-glycoprotein (P-gp) and more efficiently by breast cancer resistance protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a7f5b315272dd78f852d5637cb69d3
https://doi.org/10.1007/s13318-020-00639-z
https://doi.org/10.1007/s13318-020-00639-z
Autor:
Edyta Szałek, Agnieszka Karbownik, Tomasz Grabowski, Katarzyna Sobańska, Anna Wolc, Edmund Grześkowiak, Joanna Stanisławiak-Rudowicz
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resistant thyroid carcinoma. Neoplastic diseases are the cause of pain, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb69af2aa7351c70828f7a6a803bf1a7
https://doi.org/10.1007/s00280-020-04075-3
https://doi.org/10.1007/s00280-020-04075-3
Autor:
Tomasz Grabowski, Anna Wolc, Agnieszka Karbownik, Anna Stachowiak, Katarzyna Sobańska, Edmund Grześkowiak, Hanna Urjasz, Edyta Szałek, Agnieszka Szczecińska, Joanna Stanisławiak-Rudowicz
Publikováno v:
Pharmacological Reports
Background Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9efcfc64d468cb4c6b3f65bd58cd46cd
http://europepmc.org/articles/PMC8187206
http://europepmc.org/articles/PMC8187206
Autor:
Marek Grygier, Malgorzata Ladzinska, Bartłomiej Perek, Maciej Walczak, Piotr Buczkowski, Aneta Klotzka, Sebastian Stefaniak, Marek Jemielity, Sławomir Katarzyński, Joanna Stanisławiak-Rudowicz, Mateusz Puslecki, Maciej Lesiak
Publikováno v:
Kardiologia polska. 80(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cb0836578a4a019c28ba21fcc1fdbc
https://pubmed.ncbi.nlm.nih.gov/34643258
https://pubmed.ncbi.nlm.nih.gov/34643258
Autor:
Radosław Jaźwiec, Edmund Grześkowiak, Miłosz Miedziaszczyk, Edyta Szałek, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Agnieszka Karbownik, Anna Wolc
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 130, Iss, Pp 110530-(2020)
Sorafenib (SR) is one of the most potent UGT (1A1, 1A9) inhibitors (in in vitro tests). The inhibition of UGT1A1 may cause hyperbilirubinaemia, whereas the inhibition of UGT1A9 and 1A1 may result in drug-drug interactions (DDIs). Tapentadol (TAP) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfac1cd94e2d54ad295a972a14a5b858
https://pubmed.ncbi.nlm.nih.gov/32712531
https://pubmed.ncbi.nlm.nih.gov/32712531
Autor:
Rodryg Ramlau, Stefan Sajdak, Paweł Knapp, Anita Chudecka-Głaz, Anita Olejek, Robert Jach, Joanna Stanisławiak-Rudowicz, Karolina Jaszczyńska-Nowinka, Andrzej Marszałek, Krystyna Adamska, Janina Markowska, Monika Szarszewska, Anna Gryboś, Anna Markowska, Marian Gryboś, Violetta Filas, Ewa Nowak-Markwitz, Wiesława Bednarek, Piotr Tomczak
Purpose Cerebral metastases develop in 10–30% of patients with breast cancer (BC) and in around 3.3 to 4% of patients with ovarian cancer (OC). The aim of the multicenter study is to investigate the correlation between the expression of estrogen al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf1d776f528623ca29a187166bb95fc
https://ruj.uj.edu.pl/xmlui/handle/item/124727
https://ruj.uj.edu.pl/xmlui/handle/item/124727
